$LH

ANDERSON KERRII B sold $954K of LH

ANDERSON KERRII B sold 3,000 shares of LABCORP HOLDINGS INC. (LH) at $318.02 ($0.95M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ANDERSON KERRII B
Published Aug 18, 2026, 12:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 12:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
low confidence
Mentioned
$LH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

This is a disclosed open-market sale of 3,000 shares at a stated price, executed under a pre-arranged Rule 10b5-1 plan, which generally limits the inference traders draw about near-term fundamentals.

02

Market read

Traders may note the insider sale for sentiment/positioning, but the 10b5-1 structure makes it less actionable as a fundamental catalyst.

03

What to watch

The article provides no information on whether other insiders sold, whether the director’s total stake is changing materially over time, or any concurrent company-specific catalysts.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, sale executed 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Labcorp Holdings Inc. (LH) by director Anderson Kerrii B.

Company-level read

Ticker impact

$LHNeutralLow confidence
Context

SEC Form 4 shows director Anderson Kerrii B sold 3,000 shares of LH on 2026-08-17 at $318.02/share under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any impact is likely short-lived.

Evidence & confidence

The filing is an open-market sale by a director executed under a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary sales.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal expectations of weaker near-term performance, so traders may still fade rallies around the disclosure window.

Key entities

  • LABCORP HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure (ticker LH).

  • ANDERSON KERRII B

    Director who sold 3,000 shares of LH under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LHMed

Why Labcorp Holdings Stock Dropped Today

Labcorp Holdings (LH) stock fell 3.3% after CMS announced plans to cut lab reimbursement rates by up to 15% starting in 2027. CMS payments accounted for 8% of Labcorp's 2025 revenue, according to its SEC filing. The company warned that reduced rates could materially impact its revenue and profitability.

$BABAMed

Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more

Alibaba shares rose 3% after its CEO announced plans for 20+ gigawatts of data centers by 2032 and launched a new chip. Quest Diagnostics and Labcorp fell 5% each due to Medicare payment adjustments. Vicor gained 9% on strong Q3 guidance. On Holding jumped 6% after setting new financial targets and a $1B share buyback plan. GameStop rose 3.5% after its CEO bought 1.2M shares.

$DGXMed

Premarket movers: Quest, Labcorp hit by CMS cuts

U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.

$LHMedAI 8/10

Why is Labcorp stock sliding today?

Labcorp (LH) stock fell 3.4% after-hours to $310 following CMS's proposal to cut Medicare lab reimbursements by up to 15% annually starting 2027. CMS claims this corrects overpayments, potentially saving $1B yearly. Truist raised its price target to $365 but kept a Buy rating. Quest Diagnostics faces similar headwinds. The selloff was sector-specific, with broader markets flat.